CytomX Therapeutics
CTMX
83 hedge funds and large institutions have $303M invested in CytomX Therapeutics in 2025 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 27 increasing their positions, 17 reducing their positions, and 12 closing their positions.
950% more capital invested
Capital invested by funds: $28.8M → $303M (+$274M)
477% more call options, than puts
Call options by funds: $2.09M | Put options by funds: $362K
142% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 12
108.83% more ownership
Funds ownership: 56.52% → 165.35% (+109%)
59% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 17
26% more funds holding
Funds holding: 66 → 83 (+17)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$22.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.7M |
| 3 |
O
OrbiMed
New York
|
+$13.6M |
| 4 |
CC
Commodore Capital
New York
|
+$12.4M |
| 5 |
PA
Perceptive Advisors
New York
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.18M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$3.32M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.7M |
| 4 |
CPC
Congress Park Capital
Saratoga Springs,
New York
|
-$932K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$823K |
CTMX Hedge Fund Activity: Q2 2025 in Review
83 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2025, worth a combined $303M — up 950% from $28.8M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CTMX positions and 12 closed out — a net gain of 17 holders — while 27 added to existing stakes and 17 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $22.5M. The largest seller was Millennium Management, cutting an estimated $4.18M.
- 83 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2025, up from 66 in Q1 2025.
- Funds reported $303M of CytomX Therapeutics stock for Q2 2025, up 950% quarter-over-quarter.
- 29 funds opened new CytomX Therapeutics positions in Q2 2025 and 12 closed out, a net change of +17 holders.
- The largest CytomX Therapeutics buyer in Q2 2025 was VR Adviser, an estimated $22.5M added.
- The largest CytomX Therapeutics seller in Q2 2025 was Millennium Management, an estimated $4.18M sold.
Based on aggregated 13F filings for Q2 2025.